MADIT-CRT Trial Shows Boston Scientific CRT-Ds Slow Progression of Heart Failure
June 23, 2009 – Boston Scientific Corp. and the University of Rochester Medical Center announced today that the landmark MADIT-CRT trial has met its primary endpoint of Boston Scientific cardiac resynchronization therapy defibrillators (CRT-Ds) being associated with a significant 29 percent reduction in death or heart failure interventions when compared to traditional implantable cardioverter defibrillators (ICDs).
High-risk, asymptomatic or mildly symptomatic New York Heart Association (NYHA) Class I and II patients were enrolled in MADIT-CRT. The MADIT-CRT Executive Committee expects to present and publish the trial's full results later this year.
MADIT-CRT, sponsored exclusively by Boston Scientific, demonstrates that early intervention with cardiac resynchronization therapy can slow the progression of heart failure. It is the world's largest randomized NYHA Class I/II CRT-D trial, with more than 1,800 patients enrolled at 110 centers in 14 countries. Principal Investigator Arthur J. Moss, M.D., professor of medicine at the University of Rochester Medical Center, is leading the trial.
Currently, patients must be in NYHA Class III/IV heart failure to be indicated for CRT-D therapy. However, approximately 70 percent of all heart failure patients in the U.S. fall into class I or II.
For more information: www.bostonscientific.com
More like this
- FDA Panel Recommends Approval of CRT-Ds for Class I, II Heart Failure Patients
- Study Shows Women Benefit More From CRT-Ds
- Boston Scientific Completes Enrollment in MADIT-CRT Trial
- FDA Expands CRT Indication for All Heart Failure Patients
- Preliminary MADIT-CRT Trial Shows CRT-D Therapy Can Prevent Worsening Early Stage Heart Failure